Gene delivery using herpes simplex virus vectors.
Herpes simplex virus (HSV) is a neurotropic DNA virus with many favorable properties as a gene delivery vector. HSV is highly infectious, so HSV vectors are efficient vehicles for the delivery of exogenous genetic material to cells. Viral replication is readily disrupted by null mutations in immediate early genes that in vitro can be complemented in trans, enabling straightforward production of high-titre pure preparations of non-pathogenic vector. The genome is large (152 Kb) and many of the viral genes are dispensable for replication in vitro, allowing their replacement with large or multiple transgenes. Latent infection with wild-type virus results in episomal viral persistence in sensory neuronal nuclei for the duration of the host lifetime. Transduction with replication-defective vectors causes a latent-like infection in both neural and non-neural tissue; the vectors are non-pathogenic, unable to reactivate and persist long-term. The latency active promoter complex can be exploited in vector design to achieve long-term stable transgene expression in the nervous system. HSV vectors transduce a broad range of tissues because of the wide expression pattern of the cellular receptors recognized by the virus. Increasing understanding of the processes involved in cellular entry has allowed preliminary steps to be taken towards targeting the tropism of HSV vectors. Using replication-defective HSV vectors, highly encouraging results have emerged from recent pre-clinical studies on models of neurological disease, including glioma, peripheral neuropathy, chronic pain and neurodegeneration. Consequently, HSV vectors encoding appropriate transgenes to tackle these pathogenic processes are poised to enter clinical trials.
Burton
Edward A
EA
Department of Clinical Neurology, University of Oxford, United Kingdom.
Fink
David J
DJ
Glorioso
Joseph C
JC
D000818:Animals; D016543:Central Nervous System Neoplasms / Q000235:genetics / Q000628:therapy; D003673:Defective Viruses / Q000235:genetics; D016503:Drug Delivery Systems / Q000379:methods; D015967:Gene Expression Regulation, Viral; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000494:pharmacology; D005910:Glioma / Q000235:genetics / Q000628:therapy; D006561:Herpes Simplex / Q000235:genetics; D006801:Humans; D009420:Nervous System / Q000187:drug effects / Q000821:virology; D018139:Simplexvirus / Q000235:genetics* / Q000502:physiology; D019076:Transgenes; D014779:Virus Replication